MK-801-induced dystonia in cebus monkeys

Area of Science:

• Neuropharmacology
• Movement Disorders
• Primate Models

Background:

• MK-801 (dizocilpine) is a noncompetitive N-methyl-D-aspartate antagonist known to induce dystonia in non-human primates.
• Understanding the neurochemical basis of MK-801-induced dystonia is crucial for developing effective treatments for similar movement disorders.

Purpose of the Study:

• To investigate the effects of various dopaminergic, anticholinergic, and other agents on MK-801-induced dystonia in Cebus apella monkeys.
• To elucidate the neurobiological mechanisms underlying MK-801-induced dystonia by comparing its pharmacological profile to that of dopamine antagonist-induced dystonia.

Main Methods:

• Seven Cebus apella monkeys were treated with MK-801 (0.08 mg/kg) to induce dystonia.
• The effects of dopamine D1 antagonist (NNC 756), dopamine D2 antagonist (raclopride), atypical antipsychotic (clozapine), dopamine D1 agonist (SKF 81297), dopamine D2/D3 agonist (quinpirole), anticholinergic (biperiden), amphetamine, and benzodiazepine (midazolam) on MK-801-induced dystonia were assessed.

Main Results:

• Dopamine D1 and D2 antagonists, dopamine agonists, biperiden, and amphetamine did not significantly alter MK-801-induced dystonia.
• Clozapine (2.0 mg/kg) and midazolam (0.4 and 1.0 mg/kg) significantly reduced the severity of MK-801-induced dystonia.
• Unlike dopamine antagonist-induced dystonia, MK-801-induced dystonia was not antagonized by dopamine agonists or biperiden.

Conclusions:

• MK-801-induced dystonia appears to involve different neurochemical pathways than dystonia caused by dopamine antagonists.
• Midazolam's efficacy suggests a role for enhanced GABAergic tone in alleviating MK-801-induced dystonia.
• Clozapine's effect may relate to its complex pharmacology, potentially involving glutamatergic mechanisms.